Karakteristik Ketebalan Makula Sentral Sebelum dan Sesudah Injeksi IntravitrealBevacizumab di RSKM Padang Eye Center Periode Januari 2018 – Januari 2019

Abstract

Macular edema is a common cause of vision disturbing. Fluid accumulation in the retina and increased thickness of the retina cause damage to the blood retinal barrier. Intravitreal anti-VEGF (bevacizumab) injection aims to reduce VEGF activity, where retinal vein occlusion (RVO) induces an increase in VEGF levels which causes an increase in vascular permeability and results in macular edema. The aim of this study was to determine the central macular thickness before and after intravitreal injection of bevacizumab in patients with central retinal vein occlusion and branch retinal vein occlusion through observing the results of OCT (Optical Coherence Tomography) examination. This research is a retrospective descriptive study based on the results of medical records tracing of 8 RVO patients in the Padang Eye Center Hospital for the period January 2018 to January 2019. The study was conducted in March to April 2020. The study subjects consisted of 8 people (8 eyes) consisting of 2 men (25.0%) and 6 women (75.0%). The age range ranges from 41-80 years. The thickness of the central macula at the start was found to be majority > 300 μm, as many as 7 people (87.5%), while ≤ 300 μm was 1 person (12.5%). One month after injection found the majority of central macular thickness ≤ 300 μm by 5 people (62.5%), while> 300 μm is as many as 3 people (37.5%). All patients experienced a decrease in central macular thickness in 8 subjects (100%).